OncoMatch/Clinical Trials/NCT02476786
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Is NCT02476786 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for breast cancer.
Treatment: Goserelin · Anastrozole · Exemestane · Fulvestrant · Tamoxifen — Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors can be identified. These trials have also demonstrated that there are not adverse effects on overall outcome if women are treated with neoadjuvant endocrine therapy for several months prior to definitive treatment. A new standard of care needs to be defined for elderly women with good prognosis estrogen receptor (ER)+ tumors, since these women may benefit from endocrine therapy alone to treat their cancer without compromising local and distant control. The investigators hypothesize that endocrine therapy alone provides adequate local and systemic control of breast cancer in a subpopulation of women 70 or older with ER+ breast cancer and low Ki67 scores.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (positive)
Disease must be ER+
Required: HER2 (ERBB2) wild-type (negative)
Disease must be...HER2-
Required: MKI67 proliferative index ≤ 30% or low to intermediate mitotic index (≤ 30% or low to intermediate)
Ki67 score/proliferative index ≤ 30% or low to intermediate mitotic index
Disease stage
Required: Stage N0-1
cT1 or T2, N0-1, and M0
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: surgery
Prior surgery for this cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify